Priovant has begun enrolling a seamless Phase 2b/3 trial of brepocitinib in lichen planopilaris (LPP), with first patients dosed in March 2026. The move extends an already busy late-stage program for the oral JAK1/TYK2 inhibitor, which is under FDA Priority Review for dermatomyositis with a PDUFA action date in Q3 2026. Additional milestones include Phase 3 topline in non-infectious uveitis and Phase 3 initiation in cutaneous sarcoidosis in the second half of 2026.
The core development is a potentially registrational program in an orphan inflammatory scalp disorder with no approved therapies. LPP is characterized by immune-mediated destruction of the follicular bulge, leading to scarring alopecia and sensory symptoms that are difficult to control with off-label steroids, antimalarials, and other immunosuppressants. Priovant is leaning on a mechanistic rationale for dual JAK1/TYK2 inhibition and signals from an investigator-initiated, placebo-controlled study to justify the accelerated, seamless design.
Strategically, this is a franchise build rather than a single-asset bet. If brepocitinib secures approval in dermatomyositis, Priovant will have immediate commercial infrastructure in overlapping rheumatology-dermatology channels, easing subsequent launches in LPP and other niche inflammatory indications. The seamless Phase 2b/3 construct is an efficiency play: it allows dose selection and early signal vetting to flow directly into confirmatory testing without a protocol reset, compressing timelines and conserving a small patient pool. It also positions the company to capture multiple rare-disease labels where pathobiology converges on type I/II interferons and IL-12/23 signaling.
For sites, the program represents a specialized but attractive opportunity. LPP patients are concentrated in academic dermatology and trichology clinics, and enrollment will likely require biopsy-confirmed diagnosis and evidence of active inflammation rather than late-stage scarring. Expect operational emphasis on standardized scalp imaging, central pathology, and robust patient-reported outcomes for pain, itch, and burning—areas where ePROs and remote assessments can reduce visit burden even as core evaluations remain in-clinic. CROs will need to solve for a narrow referral base, variable diagnostic practices, and a small eligible population that may present late. Protocol choices around background therapies and the ethics of placebo exposure in a scarring disease will be critical to site engagement and retention.
Regulatory scrutiny will center on safety and endpoint selection. JAK pathway agents carry class concerns on malignancy, MACE, and thromboembolism; although TYK2-selective drugs have shown a different profile, brepocitinib’s dual JAK1/TYK2 mechanism will warrant conservative monitoring. The sponsor will need to reconcile immunosuppressive risk in a population already reported to have higher skin cancer incidence, manage lab surveillance, and define stopping rules around emerging adverse events. On efficacy, FDA will expect clinically meaningful measures beyond symptom relief, likely tied to halting inflammatory activity and preserving hair in affected regions, supplemented by histology or imaging-based assessments. There is little precedent for registrational endpoints in LPP, raising both opportunity and risk.
Near term, watch for the posted protocol to clarify primary endpoints, allowance of background immunomodulators, adaptive features, and sample size assumptions. Enrollment velocity will be an immediate signal of feasibility, given a U.S. prevalence around 100,000 and heterogeneous presentation. Cross-program safety integration across dermatomyositis, uveitis, sarcoidosis, and LPP will shape both regulatory decision-making and payer positioning. The key questions are whether Priovant can demonstrate arrest of disease activity within a practical treatment window, sustain that effect over time, and do so with a safety margin acceptable for chronic use in a scarring disorder with few alternatives.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
